BREAST CANCER TRIPLE NEGATIVE Clinical Trials

37 clinical trials for BREAST CANCER TRIPLE NEGATIVE across international registries, including 16 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab — RECRUITING
• Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer — RECRUITING · PHASE2
• A PHASE II STUDY OF FIRST-LINE SACITUZUMAB GOVITECAN IN ADVANCED UNTREATED TRIPLE NEGATIVE BREAST CANCER PATIENT — RECRUITING · PHASE2
• TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer — RECRUITING · PHASE1
• OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY — RECRUITING
• A PHASE III, OPEN-LABEL, RANDOMISED STUDY OF NEOADJUVANT DATOPOTAMAB DERUXTECAN (DATO-DXD) PLUS DURVALUMAB FOLLOWED BY ADJUVANT DURVALUMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED TRIPLE-NEGATIVE OR HORMONE RECEPTOR-LOW/HER2-NEGATIVE BREAST CANCER — RECRUITING · PHASE3
• A PHASE 3 OPEN-LABEL, RANDOMISED STUDY OF DATOPOTAMAB DERUXTECAN¿(DATODXD) WITH OR WITHOUT DURVALUMAB VERSUS INVESTIGATOR¿S CHOICE OF THERAPY IN PATIENTS WITH STAGE I-III TRIPLE-NEGATIVE BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN THE BREAST AND/OR AXILLARY LYMPH NODES AT SURGICAL RESECTION FOLLOWING NEOADJUVANT SYSTEMIC THERAPY — RECRUITING · PHASE3
• A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN¿S CHOICE IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED, INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHOSE TUMORS DO NOT EXPRESS PD-L1 OR IN PATIENTS PREVIOUSLY TREATED WITH ANTI-PD-(L)1 AGENTS IN THE EARLY SETTING WHOSE TUMORS DO EXPRESS PD-L1 — RECRUITING · PHASE3
• A PHASE II STUDY OF CFI-400945 AND DURVALUMAB IN PATIENTS WITH ADVANCED/METASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC) — RECRUITING · PHASE2
• A PHASE I/II OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF EDP 1503 ALONE AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED METASTATIC COLORECTAL CARCINOMA, TRIPLE-NEGATIVE BREAST CANCER, AND CHECKPOINT INHIBITOR RELAPSED TUMOURS — RECRUITING · PHASE1
• "A PHASE IB/II, 2-STAGE, OPEN-LABEL, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DURVALUMAB (MEDI4736) IN COMBINATION WITH PACLITAXEL AND MULTIPLE NOVEL ONCOLOGY THERAPIES AND DURVALUMAB (MEDI4736) + PACLITAXEL FOR FIRST-LINE METASTATIC TRIPLE NEGATIVE BREAST CANCER (BEGONIA)." — RECRUITING · PHASE1
• A RANDOMIZED, PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MK-3475 AS ADJUVANT THERAPY FOR TRIPLE RECEPTOR-NEGATIVE BREAST CANCER WITH ¿ 1 CM RESIDUAL INVASIVE CANCER OR POSITIVE LYMPH NODES (YPN+) AFTER NEOADJUVANT CHEMOTHERAPY — RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PHASE III CLINICAL TRIAL OF NEOADJUVANT CHEMOTHERAPY WITH ATEZOLIZUMAB OR PLACEBO IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER FOLLOWED BY ADJUVANT CONTINUATION OF ATEZOLIZUMAB OR PLACEBO — RECRUITING · PHASE3
• A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER — RECRUITING · PHASE3
• A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE PEMBROLIZUMAB PLUS CHEMOTHERAPY VS PLACEBO PLUS CHEMOTHERAPY AS NEOADJUVANT THERAPY AND PEMBROLIZUMAB VS PLACEBO AS ADJUVANT THERAPY FOR TRIPLE NEGATIVE BREAST CANCER (TNBC) — RECRUITING · PHASE3
• PHASE 1B, OPEN-LABEL, MULTI-CENTER STUDY TO CHARACTERIZE THE SAFETY, TOLERABILITY AND PHARMACODYNAMICS (PD) OF PDR001 IN COMBINATION WITH CJM112, EGF816, ILARIS (CANAKINUMAB) OR MEKINIST (TRAMETINIB) — RECRUITING · PHASE1
• A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer — WITHDRAWN · PHASE1
• REBOOTING SENSITIVITY TO CHECKPOINT BLOCKADE THERAPY IN TRIPLE-NEGATIVE BREAST CANCER WITH ISUNAKINRA (RESETT- I) — NOT_YET_RECRUITING
• Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) — NOT_YET_RECRUITING · PHASE2
• FMT IN TRIPLE NEGATIVE BREAST CANCER GUIDED BY CTDNA (FRIDA) — NOT_YET_RECRUITING
• DETERMINE WHETHER ADMINISTERING CELECOXIB DURING RADIOTHERAPY CAN REDUCE THE RISK OF RECURRENCE OF TRIPLE-NEGATIVE BREAST CANCER. PILOT STUDY — NOT_YET_RECRUITING
• A PHASE 2, UMBRELLA STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF INVESTIGATIONAL AGENTS FOR NEWLY DIAGNOSED, HIGH-RISK, EARLYSTAGE TRIPLE-NEGATIVE BREAST CANCER — NOT_YET_RECRUITING · PHASE2
• IL-1 INHIBITION FOR PATIENTS WITH EARLY STAGE TRIPLE NEGATIVE AND ER-LOW BREAST CANCER: A WINDOW-OF-OPPORTUNITY STUDY — NOT_YET_RECRUITING
• EFFICACY OF INTRALESIONAL IL-2 FOR RESECTABLE TRIPLE NEGATIVE BREAST CANCER — NOT_YET_RECRUITING
• A PHASE 1 STUDY OF BMS-986360/CC-90001 ALONE AND IN COMBINATION WITH CHEMOTHERAPY OR NIVOLUMAB IN ADVANCED SOLID TUMORS — COMPLETED · PHASE1
• A PHASE I TRIAL OF THE COMBINATION OF OLAPARIB AND NAVITOCLAX IN WOMEN WITH HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER AND HER2- NEGATIVE BREAST CANCER — COMPLETED · PHASE1
• A RANDOMIZED PHASE 2 STUDY OF TEMOZOLOMIDE MONOTHERAPY OR IN COMBINATION WITH OLAPARIB IN PATIENTS WITH METHYLATED 06-METHYLGUANINE-DNA METHYLTANSFERASE (MGMT) PRE-TREATED TRIPLE NEGATIVE BREAST CANCER (TNBC) — NOT_YET_RECRUITING · PHASE2
• A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DBA AFTER DEFINITIVE THEREAPY (ZEST) — COMPLETED · PHASE3
• A GLOBAL, MULTICENTER, THREE ARMS, OPEN-LABEL RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NANOSOMAL DOCETAXEL LIPID SUSPENSION COMPARED TO TAXOTERE® (DOCETAXEL INJECTION CONCENTRATE) IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE TO PRIOR CHEMOTHERAPY — NOT_YET_RECRUITING
• A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE-EXPLORATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF AMG 650 IN SUBJECTS WITH ADVANCED SOLID TUMORS — COMPLETED · PHASE1
• A PHASE IB, MULTICENTER, OPEN-LABEL DOSE ESCALATION AND EXPANSION PLATFORM STUDY OF SELECT IMMUNOTHERAPY COMBINATIONS IN ADULT PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER — NOT_YET_RECRUITING · PHASE1
• Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC — WITHDRAWN · PHASE1
• "A PHASE IB OPEN-LABEL, RANDOMIZED, THREE-ARM, MULTICENTER STUDY OF LAG525 GIVEN IN COMBINATION WITH SPARTALIZUMAB (PDR001), OR WITH SPARTALIZUMAB AND CARBOPLATIN, OR WITH CARBOPLATIN, AS FIRST OR SECOND LINE THERAPY IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER." — COMPLETED · PHASE1
• Neoadjuvant Goserelin for Triple Negative Breast Cancer — OTHER · PHASE2
• A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER. — COMPLETED · PHASE3
• A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY COMPARED WITH PLACEBO AND CHEMOTHERAPY IN PATIENTS WITH PRIMARY INVASIVE TRIPLE-NEGATIVE BREAST CANCER — COMPLETED · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF PEMBROLIZUMAB (MK-3475) PLUS CHEMOTHERAPY VS PLACEBO PLUS CHEMOTHERAPY FOR PREVIOUSLY UNTREATED LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER - (KEYNOTE-355) — COMPLETED · PHASE3

Refine this search